Video: Who Am I?| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: hospital

The ACR Introduces New Reproductive Health Guideline

Susan Bernstein  |  March 4, 2020

The evidence-based guideline includes contraceptive recommendations and suggestions for rheumatologists co-managing patients with obstetrician-gynecologists and other specialists.

Filed under:Clinical Criteria/Guidelines Tagged with:Clinical GuidelinesEliza ChakravartyLisa R. SammaritanoMDMSreproductive health

Sports Doctors May Accidentally Prescribe Banned Steroids

Lisa Rapaport  |  March 4, 2020

(Reuters Health)—Sports physicians routinely prescribe corticosteroids to athletes for conditions, such as inflammation, asthma and allergies, but not all of them know which forms of these drugs are banned under anti-doping rules, a study suggests. The survey of 603 physicians from 30 countries found four in five prescribe oral corticosteroids to athletes, one of the…

Filed under:Drug Updates

Phase 3 Results for Olokizumab in RA Patients

Michele B. Kaufman, PharmD, BCGP  |  March 3, 2020

In a recent study, olokizumab proved safe and effective for treating the signs and symptoms of RA and improving patients’ physical function…

Filed under:Drug Updates Tagged with:2019 ACR/ARP Annual MeetingolokizumabRheumatoid Arthritis (RA)

Pearls & Myths: Experts Offer Advice & Dispel Myths

Thomas R. Collins  |  February 25, 2020

GCA, GPA, myositis, new research—rheumatology care keeps clinicians on their toes & requires them to stay up to date…

Filed under:CareerCareer DevelopmentMeeting ReportsProfessional Topics Tagged with:2019 ACR/ARP Annual Meeting

Can Lupus Be Prevented? Research Reveals Clues to Who’s Most Likely to Transition to Classified Disease

Susan Bernstein  |  February 25, 2020

How does a patient transition from health to active SLE? This question is the crux of the research conducted by Judith A. James, MD, PhD, and colleagues…

Filed under:ConditionsSystemic Lupus Erythematosus Tagged with:2019 ACR/ARP Annual Meetingenvironmental factorgeneticSLEsystemic lupus erythematosus (SLE)

Low-Dose Methotrexate Can Cause Adverse Effects

Will Boggs, MD  |  February 19, 2020

NEW YORK (Reuters Health)—Low-dose methotrexate can be associated with gastrointestinal, pulmonary, infectious, hematologic and other adverse effects, according to an analysis of the Cardiovascular Inflammation Reduction Trial (CIRT). “Methotrexate is not a benign drug, even at dosages used for rheumatic diseases,” Daniel H. Solomon, MD, MPH of Brigham and Women’s Hospital, Boston, tells Reuters Health…

Filed under:Drug Updates Tagged with:adverse eventsMethotrexate

FDA Advisory Committees Reject Oxycodegol (NKTR-181) Application

Michele B. Kaufman, PharmD, BCGP  |  February 19, 2020

FDA advisory committees rejected the new drug application for oxycodegol, an opioid analgesic, due to a lack of data regarding it’s potential for abuse…

Filed under:AnalgesicsDrug Updates Tagged with:FDANKTR-181opioidoxycodegolPain ManagementU.S. Food and Drug Administration (FDA)

Sodium-Glucose Cotransporter-2 Inhibitors May Decrease Gout Risk in Some Patients

Lara C. Pullen, PhD  |  February 19, 2020

Recent research assessed the risk of gout in patients with type 2 diabetes mellitus prescribed sodium-glucose cotransporter-2 (SGLT2) inhibitors compared with those prescribed a glucagon-like peptide-1 (GLP-1) agonist. The study found patients on the SGLT2 inhibitor had a lower rate of gout, suggesting SGLT2 inhibitors may actually reduce the risk of gout among this patient population…

Filed under:ConditionsGout and Crystalline Arthritis Tagged with:GoutSGLT2 inhibitorssodium-glucose cotransporter-2 (SGLT2) inhibitorstype II diabetes

Proposed Changes May Loosen Federal Fraud & Abuse Laws

Steven M. Harris, Esq.  |  February 13, 2020

The Stark law and the Anti-Kickback Statute (AKS) are the U.S. healthcare system’s primary fraud and abuse laws, and highly anticipated proposed reform plans from the Centers for Medicare & Medicaid Services (CMS) and the Office of Inspector General (OIG) were finally unveiled on Oct. 17, 2019. The proposed reforms would 1) clarify certain requirements…

Filed under:Legal Updates Tagged with:Anti-Kickback StatuteCenters for Medicare & Medicaid Services (CMS)Stark Law

5 Challenges in the Treatment & Diagnosis of Lupus

Kelly Tyrrell  |  February 13, 2020

A recent study published in Lupus Science & Medicine lays out five of the top barriers impeding progress in lupus diagnosis and treatment.1 The Addressing Lupus Pillars for Health Advancement project (ALPHA), led by the Lupus Foundation of America (LFA), researchers at the Tufts School of Medicine Center for the Study of Drug Development (Tufts…

Filed under:ConditionsResearch RheumSystemic Lupus Erythematosus Tagged with:Access to careadherenceBiomarkersclinical trialsheterogeneitySocioeconomic Impact

  • « Previous Page
  • 1
  • …
  • 107
  • 108
  • 109
  • 110
  • 111
  • …
  • 326
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences